J. Frohlich

发表

The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort.

G. Mancini, S. Lear, D. Gasevic, 2012, Metabolism: clinical and experimental.

Are Cardiovascular Disease and Osteoporosis Directly Linked?

K. Khan, H. McKay, D. Warburton, 2004, Sports medicine.

Statins and bones.

J. Frohlich, M. Moghadasian, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

Walker, R. Collins, V. Fuster, 1994 .

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

J. Frohlich, M. Dobiášová, 2001, Clinical biochemistry.

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

C. Sensen, S. Scherer, M. Hayden, 1999, Nature Genetics.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia.

D. Gaudet, B. McCrindle, R. Hegele, 2014, The Canadian journal of cardiology.

Association of skin cholesterol content, measured by a noninvasive method, with markers of inflammation and Framingham risk prediction.

Lisa Kuramoto, G. Mancini, M. Schulzer, 2002, The American journal of cardiology.

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.

D. Gómez-Coronado, J. Frohlich, R. Knopp, 1994, The American journal of medicine.

Recommendations for the Management of Dyslipidemia and the Prevention of Cardiovascular Disease: 200

R. McPherson, J. Frohlich, J. Genest, 2003 .

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.

P. Talmud, J. Ansquer, J. Kastelein, 2004, Pharmacogenetics.

Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291-->Ser mutation in the human LPL gene.

M. Hayden, J. Kastelein, Ming‐Sun Liu, 1995, Arteriosclerosis, thrombosis, and vascular biology.

High frequency of mutations in the human lipoprotein lipase gene in pregnancy-induced chylomicronemia: possible association with apolipoprotein E2 isoform.

M. Hayden, R. McPherson, Ming‐Sun Liu, 1994, Journal of lipid research.

Cholesterol and triglyceride fatty acid synthesis in apolipoprotein E2-associated hyperlipidemia.

D. Schoeller, J. Frohlich, P. J. Jones, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Ancel Keys and the lipid hypothesis: From early breakthroughs to current management of dyslipidemia

A. Ignaszewski, J. Andrade, J. Frohlich, 2009 .

The analysis by Manuel and colleagues creates controversy with headlines, not data

R. McPherson, G. Fodor, J. Frohlich, 2005, Canadian Medical Association Journal.

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment

A. Keech, G. Walldius, J. Frohlich, 2003, The Lancet.

Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula.

J. Frohlich, A. Sniderman, J. Bergeron, 2003, Clinical biochemistry.

Phenotypic heterogeneity of sitosterolemia Published, JLR Papers in Press, September 16, 2004. DOI 10.1194/jlr.M400310-JLR200

R. Hegele, J. Frohlich, Jian Wang, 2004, Journal of Lipid Research.

Canned Soup Consumption and Urinary Bisphenol A: A Randomized Crossover Trial

P. Jones, J. Frohlich, V. Ramprasath, 2011 .

Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia.

G. Francis, G. Mancini, J. Frohlich, 2020, Journal of the American College of Cardiology.

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment

A. Keech, C. Furberg, A. Wägner, 2003, The Lancet.

Cholesterol-Lowering Foods and Reduction in Serum Cholesterol Levels—Reply

P. Jones, J. Frohlich, V. Ramprasath, 2011 .

Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence.

J. Frohlich, M. Moghadasian, 1999, The American journal of medicine.

Implementing phytosterols into medical practice as a cholesterol-lowering strategy: overview of efficacy, effectiveness, and safety.

P. Jones, C. Marinangeli, J. Frohlich, 2014, The Canadian journal of cardiology.

Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

J. Frohlich, A. Sniderman, J. Bergeron, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Analysis of familial hypoalphalipoproteinemia syndromes

J. Frohlich, P. Pritchard, 1992, Molecular and Cellular Biochemistry.

The clinical significance of serum high density lipoproteins.

J. Frohlich, P. Pritchard, 1989, Clinical biochemistry.

UvA-DARE (Digital Academic Repository) Age and residuel cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes

A. Brooks-Wilson, K. Roomp, T. Suda, 2016 .

Age and residuel cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA 1 heterozygotes

M. Hayden, A. Brooks-Wilson, J. Kastelein, 2000 .

Familial high‐density‐lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent

J. Kastelein, J. Frohlich, D. Erkelens, 1992, Journal of internal medicine.

Modification of the relationship between simple anthropometric indices and risk factors by ethnic background.

S. Lear, C. Birmingham, J. Frohlich, 2003, Metabolism: clinical and experimental.

Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses: comparison to controls without personal and family history of atherosclerosis.

J. Frohlich, K. Rašlová, B. Smolková, 2001, Metabolism: clinical and experimental.

Dietary measures and exercise training contribute to improvement of endothelial function and atherosclerosis even in patients given intensive pharmacologic therapy.

A. Ignaszewski, M. Schulzer, J. Frohlich, 2006, Journal of cardiopulmonary rehabilitation.

Visceral Adipose Tissue, a Potential Risk Factor for Carotid Atherosclerosis: Results of the Multicultural Community Health Assessment Trial (M-CHAT)

G. Mancini, S. Lear, C. Birmingham, 2007, Stroke.

Chemical precipitation of apolipoprotein B-containing lipoproteins facilitates determination of LDL particle size.

J. Frohlich, J. Hill, L. Adler, 2000, Clinical biochemistry.

Lipid and lipoprotein changes during the seven days off oral contraception in women using two triphasic preparations.

J. Frohlich, R. Percival-Smith, B. Abercrombie, 1988, Contraception.

Structural and functional assessment of high-density lipoprotein heterogeneity.

J. Frohlich, M. Dobiášová, 1994, Clinical chemistry.

Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene.

M. Hayden, D. Ginzinger, J. Brunzell, 1993, The Journal of clinical investigation.

Differences in cardiovascular risks in the aboriginal and non-aboriginal people living in Bella Coola, British Columbia.

J. Frohlich, M. V. Monsalve, H. Thommasen, 2005, Medical science monitor : international medical journal of experimental and clinical research.

Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

J. Montaner, G. Bondy, J. Frohlich, 2004, Diabetes care.

The impact of dietary changes and dietary supplements on lipid profile.

A. Ignaszewski, J. Frohlich, Jingbo Huang, 2011, The Canadian journal of cardiology.

Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.

Lawrence A Leiter, P. Jones, J. Frohlich, 2011, JAMA.

Use of metabolic drugs and fish oil in HIV‐positive patients with metabolic complications and associations with dyslipidaemia and treatment targets

B. Yip, R. Hogg, G. Bondy, 2007, HIV medicine.

A review on lecithin:cholesterol acyltransferase deficiency.

J. Frohlich, R. Saeedi, Min Li, 2015, Clinical biochemistry.

Vascular Calcifications in Homozygote Familial Hypercholesterolemia

G. Francis, R. Hegele, R. McPherson, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.

R. McPherson, G. Fodor, J. Frohlich, 1998, The Canadian journal of cardiology.

Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: assessment and treatment.

J. Frohlich, 1995, The Canadian journal of cardiology.

Appropriateness of current thresholds for obesity-related measures among Aboriginal people

S. Lear, C. Birmingham, J. Frohlich, 2007, Canadian Medical Association Journal.

Visceral adipose tissue accumulation differs according to ethnic background : results of the Multicultural Community Health Assessment Trial ( M-CHAT ) 1 3

S. Lear, C. Birmingham, J. Frohlich, 2007 .

Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study

G. Mancini, A. Ignaszewski, J. Frohlich, 2008, BMC clinical pharmacology.

Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients on dialysis.

C. E. Reeve, J. Frohlich, R. Mcleod, 1984, Kidney international.

Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up.

John S. Hill, J. Frohlich, A. Ayyobi, 2004, Atherosclerosis.

Canadian Cardiovascular Society Position Statement onFamilial Hypercholesterolemia

D. Gaudet, R. Hegele, J. Brophy, 2014 .

Detection of early atherosclerosis with B mode carotid ultrasonography: assessment of a new quantitative approach.

J. Frohlich, G. Mancini, A. Aminbakhsh, 1999, Clinical and investigative medicine. Medecine clinique et experimentale.

Extensive lifestyle management intervention following cardiac rehabilitation: pilot study.

A. Ignaszewski, S. Lear, J. Frohlich, 2001, Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses.

Lipid clinics/cardiovascular risk reduction clinics: current state and future consideration.

J. Frohlich, K. Kingsbury, 2001, Advances in experimental medicine and biology.

Hypertriglyceridemic hyperapoB in type 2 diabetes.

J. Frohlich, B. Lamarche, A. Sniderman, 2002, Diabetes care.

Modified lipoproteins and cardiovascular risk.

J. Frohlich, W. Aldahi, Jiri J. Frohlich, 2001, Advances in experimental medicine and biology.

The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences.

S. Lear, C. Birmingham, J. Frohlich, 2003, Metabolism: clinical and experimental.

Simplified Canadian Definition for Familial Hypercholesterolemia.

G. Francis, D. Gaudet, J. Tu, 2018, The Canadian journal of cardiology.

Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action.

B. McManus, B. Rodrigues, J. Frohlich, 1999, Circulation.

Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia.

J. Frohlich, K. Humphries, Daniel T Holmes, 2005, Clinical chemistry.

Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.

D. Rader, J. Frohlich, M. Clerc, 1994, The Journal of clinical investigation.

Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.

M. Hayden, J. Frohlich, J. Hill, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.

G. Francis, J. Frohlich, L. Brunham, 2017, The Canadian journal of cardiology.

Effects of alcohol on plasma lipoprotein metabolism.

J. Frohlich, 1996, Clinica chimica acta; international journal of clinical chemistry.

Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro.

J. Frohlich, K. O, 1995, Journal of lipid research.

Liver biochemistry abnormalities in a quaternary care lipid clinic database.

J. Frohlich, S. Sirrs, E. Yoshida, 2008, Annals of hepatology.

Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease.

J. Frohlich, M. Dobiášová, L. Adler, 2004, Physiological research.

Lack of regression of atherosclerotic lesions in phytosterol-treated apo E-deficient mice.

B. McManus, J. Frohlich, M. Moghadasian, 1999, Life sciences.

Effects of Multidisciplinary Cardiac Rehabilitation Program on Plasma Lipid Profile

A. Ignaszewski, J. Frohlich, J. St-Amand, 1999 .

Relation of anthropometric parameters to the functional assessment of HDL particle size in three ethnic cohorts.

S. Lear, J. Frohlich, H. Zakeri, 2006, Asia Pacific journal of clinical nutrition.

Oxidized low-density lipoprotein in experimental focal glomeruloscierosis

U. Steinbrecher, J. Frohlich, S. Innis, 2015 .

Oxidized low-density lipoprotein in experimental focal glomerulosclerosis.

U. Steinbrecher, J. Frohlich, S. Innis, 1993, Kidney international.

Intraobserver and interobserver reliability of waist circumference and the waist-to-hip ratio.

S. Lear, C. Birmingham, J. Frohlich, 2001, Obesity research.

The role of apoproteins in disorders of lipoprotein metabolism.

J. Frohlich, P. Pritchard, D. Seccombe, 1989, Clinical biochemistry.

Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease.

J. Frohlich, M. Dobiášová, D. Sparks, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Lecithin:cholesterol acyltransferase in familial HDL deficiency (Tangier disease).

J. Frohlich, A. Lacko, R. Mcleod, 1988, Biochimica et biophysica acta.

The effects of age, smoking, and alcohol on routine laboratory tests.

M. Chan-yeung, M. Schulzer, J. Frohlich, 1981, American journal of clinical pathology.

High‐density lipoprotein subclasses and esterification rate of cholesterol in children: effect of gender and age

J. Frohlich, M. Dobiášová, Z. Urbanová, 1998, Acta paediatrica.

Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia.

J. Frohlich, J. Hill, P. Pritchard, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men.

J. Frohlich, M. Dobiášová, P. Pritchard, 1992, Journal of lipid research.

Plasma lipoprotein abnormalities in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency.

J. Frohlich, R. Mcleod, P. Pritchard, 1988, Metabolism: clinical and experimental.

Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.

M. Hayden, S. Rabkin, J. Frohlich, 1988, Atherosclerosis.

Cholesteryl ester transfer activity in plasma of patients with familial high-density lipoprotein deficiency.

J. Frohlich, D. Sparks, P. Pritchard, 1988, Clinical chemistry.

Hypoalphalipoproteinemia resembling fish eye disease.

M. Hayden, L. Wadsworth, J. Frohlich, 2009, Acta medica Scandinavica.

DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias.

M. Hayden, S. Rabkin, J. Frohlich, 1987, American journal of human genetics.

Erythrocyte membrane alterations and plasma lipids in patients with chylomicronemia and in Tangier disease.

J. Frohlich, D. Godin, 1986, Clinical biochemistry.

Serial measurement of plasma cholesterol and lecithin:cholesterol acyl transferase activity in adults receiving total parenteral nutrition.

J. Frohlich, S. Innis, R. Mcleod, 1985, JPEN. Journal of parenteral and enteral nutrition.

Cholesteryl ester transfer activity in plasma measured by using solid-phase-bound high-density lipoprotein.

J. Frohlich, P. Cullis, D. Sparks, 1987, Clinical chemistry.

Promotion of sterol efflux and net transport by apolipoprotein E in lecithin:cholesterol acyltransferase deficiency.

C. Fielding, P. Fielding, J. Frohlich, 1982, Metabolism: clinical and experimental.

Hepatic lipase deficiency in a Middle-Eastern-Arabic male

R. Hegele, John S. Hill, J. Frohlich, 2010, BMJ Case Reports.

Hepatic lipase deficiency in a Middle-Eastern-Arabic male

R. Hegele, J. Frohlich, K. Wasan, 2010, BMJ Case Reports.

Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure.

A. Ignaszewski, J. Frohlich, K. Kingsbury, 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation.

A. Ignaszewski, J. Frohlich, K. Kingsbury, 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Detection of heterozygotes for familial lecithin: cholesterol acyltransferase (LCAT) deficiency.

J. Frohlich, R. Mcleod, K. Hon, 1982, American journal of human genetics.

The concept of precision extended to the atherogenic index of plasma.

K. Buhr, J. Frohlich, Daniel T Holmes, 2008, Clinical biochemistry.

Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High‐Dose Simvastatin

T. Lehtimäki, J. Frohlich, K. Humphries, 2007, Clinical pharmacology and therapeutics.

Asymptomatic hypothyroidism and statin-induced myopathy.

J. Frohlich, Daniel T Holmes, Daniel T. Holmes, 2007, Canadian family physician Medecin de famille canadien.

Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus.

J. Frohlich, R. Knopp, L. Jokubaitis, 1994, Journal of internal medicine. Supplement.

Response of cholesterol synthesis to cholesterol feeding in men with different apolipoprotein E genotypes.

J. Frohlich, P. J. Jones, B. F. Main, 1993, Metabolism: clinical and experimental.

Case series of type III hyperlipoproteinemia in children

J. Frohlich, M. Fung, D. Cook, 2011, BMJ Case Reports.

Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.

G. Francis, J. Frohlich, L. Brunham, 2018, The Canadian journal of cardiology.

Regional and national familial hypercholesterolemia registries: present international application, importance, and needs for Canada.

J. Frohlich, Ahmad J Al-Sarraf, M. Martinka, 2013, The Canadian journal of cardiology.

Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.

B. G. Brown, A. Chait, L. Fisher, 1998, The Canadian journal of cardiology.

Image in cardiovascular medicine. Aortic xanthomatosis with coronary ostial occlusion in a child homozygous for a nonsense mutation in ABCG8.

R. Hegele, J. Frohlich, Jian Wang, 2003, Circulation.

Common problems in the management of hypertriglyceridemia.

J. Frohlich, M. Fung, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Monocytes and macrophages in focal glomerulosclerosis in Zucker rats.

J. Frohlich, A. Magil, 1991, Nephron.

Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol.

J. Frohlich, R. Saeedi, Min Li, 2014, Clinical biochemistry.

Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport.

J. Frohlich, M. Dobiášová, Jiři Frohlich, 1999, Clinica chimica acta; international journal of clinical chemistry.

Consumption of a dietary portfolio of cholesterol lowering foods improves blood lipids without affecting concentrations of fat soluble compounds

Lawrence A Leiter, J. Frohlich, R. D. de Souza, 2014, Nutrition Journal.

Effectiveness of Colestipol Tablets vs Granules in Patients with Moderate to Severe Hypercholesterolaemia

S. Tonstad, L. Romics, J. Frohlich, 1995 .

Specificity of the commonly used enzymatic assay for plasma cholesterol determination

C. Scudamore, J. Frohlich, M. Moghadasian, 2002, Journal of clinical pathology.

Measurement of fractional esterification rate of cholesterol in plasma depleted of apoprotein B containing lipoprotein: methods and normal values.

J. Frohlich, M. Dobiášová, 1996, Physiological research.

Detection of vesicular lipoproteins in lecithin:cholesterol acyltransferase-deficient plasma by 1H-NMR spectroscopy.

J. Frohlich, P. Cullis, D. Sparks, 1989, Journal of lipid research.

Study of the components of reverse cholesterol transport in lecithin:cholesterol acyltransferase deficiency.

J. Frohlich, A. Lacko, B. Kudchodkar, 1987, Archives of biochemistry and biophysics.

[The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].

J. Frohlich, M. Dobiášová, 2000, Vnitrni lekarstvi.

Study of erythrocytes in a hereditary hemolytic syndrome (HHS): comparison with erythrocytes in lecithin:cholesterol acyltransferase (LCAT) deficiency.

J. Frohlich, D. Godin, G. Gray, 2009, Scandinavian journal of haematology.

Erythrocyte membrane alterations in lecithin:cholesterol acyltransferase deficiency.

J. Frohlich, D. Godin, G. Gray, 1978, Scandinavian journal of clinical and laboratory investigation. Supplementum.

Association between apolipoprotein E phenotype and endogenous cholesterol synthesis as measured by deuterium uptake.

D. Schoeller, J. Frohlich, P. J. Jones, 1991, Cardiovascular research.

Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence.

J. Frohlich, M. Moghadasian, Jiri Frohlich, 1999, The American journal of medicine.

Reply: To PMID 25110227.

J. Frohlich, R. Saeedi, S. Rankin, 2014, Journal of clinical lipidology.

Cardiovascular risk in patients with type 2 diabetes

J. Frohlich, M. Shanks, Daniel T Holmes, 2005, Canadian Medical Association Journal.

Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: The reply

J. Frohlich, 2000 .

Safety of statin therapy in patients with mitochondrial diseases.

J. Frohlich, A. Mattman, S. Sirrs, 2013, Journal of clinical lipidology.

Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.

J. Frohlich, R. Dufour, J. Davignon, 1993, The Canadian journal of cardiology.

Relationship between cholesteryl ester transfer activity and high density lipoprotein composition in hyperlipidemic patients.

J. Frohlich, A. Lacko, D. Sparks, 1989, Atherosclerosis.

Purification of biologically active apolipoproteins by chromatofocussing.

J. Frohlich, A. Lacko, R. Mcleod, 1986, Journal of chromatography.

Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature.

R. Hegele, J. Frohlich, D. Sullivan, 2010, Journal of clinical lipidology.

A muclticenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia

D. Hunninghake, R. Goldberg, E. Nikkilä, 1990 .

Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols.

B. McManus, J. Frohlich, M. Moghadasian, 1999, Laboratory investigation; a journal of technical methods and pathology.

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

E. Bolson, B. G. Brown, A. Chait, 2001, The New England journal of medicine.

Therapeutic Role

J. Frohlich, R. Fedorak, Christine Miclennan, 2008 .

Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk stratification.

G. Mancini, J. Frohlich, J. Grewal, 2003, Clinical and investigative medicine. Medecine clinique et experimentale.

The cornea in familial high density lipoprotein deficiency, tangier disease

A. Garner, J. Frohlich, R. Alexander, 1991 .

Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT).

S. Lear, C. Birmingham, J. Frohlich, 2007, The American journal of clinical nutrition.

Lecithin: cholesterol acyl transferase (LCAT).

J. Frohlich, R. Mcleod, K. Hon, 1982, Clinical biochemistry.

Unusual renal biopsy findings in a patient with familial lecithin:cholesterol acyltransferase deficiency.

J. Frohlich, A. Magil, W. Chase, 1982, Human pathology.

Fractional Esterification Rate of HDL Particles in Patients With Type 2 Diabetes: Relation to coronary heart disease risk factors

J. Frohlich, M. Dobiášová, M. Tan, 1998, Diabetes Care.

Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio.

J. Frohlich, M. Dobiášová, 1998, Physiological research.

Effect of labeling of plasma lipoproteins with [(3)H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma.

J. Frohlich, M. Dobiášová, T. Ohta, 2000, Journal of lipid research.

Characterization of subspecies of lipoprotein containing apolipoprotein A-I in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency.

J. Frohlich, P. Pritchard, T. Ohta, 1995, Atherosclerosis.

Characterization of subspecies of apolipoprotein A-I-containing lipoprotein in homozygotes for familial lecithin:cholesterol acyltransferase deficiency.

S. Horiuchi, J. Frohlich, Y. Ikeda, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Targeted next-generation sequencing to diagnose disorders of HDL cholesterol patient-oriented and epidemiological research

G. Francis, M. Hayden, H. Liany, 2020 .

Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort

J. Frohlich, R. Saeedi, M. Yousefi, 2014, Lipids in Health and Disease.

PO23-750 DECREASED SKELETAL MUSCLE MITOCHONDRIAL DNA IN PATIENTS TREATED WITH HIGH-DOSE SIMVASTATIN

T. Lehtimäki, R. Laaksonen, J. Frohlich, 2007 .

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

G. Bondy, J. Frohlich, M. Bennett, 2015, Lipids in Health and Disease.

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus.

J. Frohlich, J. Genest, G. Steiner, 2004, The American journal of cardiology.

Action of a microbial glycerophospholipid:cholesterol acyltransferase on plasma from normal and LCAT-deficient subjects.

J. Frohlich, R. Mcleod, J. Buckley, 1984, Journal of lipid research.

Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

Robert Dufour, Patrick Couture, Ruth McPherson, 2009 .

Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.

R. Hegele, D. Fitchett, G. Mancini, 2013, The Canadian journal of cardiology.

Advances in Experimental Dyslipidemia and Atherosclerosis

B. McManus, J. Frohlich, M. Moghadasian, 2001, Laboratory Investigation.

Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study

G. Francis, J. Frohlich, C. Taraboanta, 2011, Lipids in Health and Disease.

Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment.

J. Frohlich, M. Moghadasian, A. Batta, 2001, Metabolism: clinical and experimental.

The pathology of cornea in Tangier disease (familial high density lipoprotein deficiency).

A. Garner, J. Frohlich, R. Alexander, 1996, Journal of clinical pathology.

Use of ezetimibe results in more patients reaching lipid targets without side effects

J. Frohlich, Daniel T. Holmes, M. Vrablik, 2014 .

Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.

G. Francis, G. Mancini, J. Frohlich, 2019, Journal of the American College of Cardiology.

The British Columbia Familial Hypercholesterolemia Registry

G. Francis, A. Ignaszewski, J. Frohlich, 2013 .

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

R. Krauss, S. Humphries, C. Furberg, 2006, Journal of internal medicine.

Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada.

M. Hayden, A. Soutar, J. Frohlich, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Clinical usefulness of lipid ratios to identify men and women with metabolic syndrome: a cross-sectional study

G. Mancini, S. Lear, D. Gasevic, 2014, Lipids in Health and Disease.

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).

Steven Baker, Robert A Hegele, Jacques Genest, 2016, The Canadian journal of cardiology.

Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition

F. Clavel-Chapelon, E. Riboli, P. Vineis, 2011, Gut.

APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease.

J. Frohlich, A. Ayyobi, J. Hill, 2004, Atherosclerosis.

Lipoprotein lipase and apoE polymorphisms: relationship to hypertriglyceridemia during pregnancy.

J. Frohlich, S. McGladdery, Jiri J. Frohlich, 2001, Journal of lipid research.

Extreme hypertriglyceridemia following intravenous heparin infusion.

J. Frohlich, Nafila B Al Riyami, 2008, Clinical biochemistry.

Targeted next-generation sequencing to diagnose disorders of HDL cholesterol[S]

G. Francis, M. Hayden, H. Liany, 2015, Journal of Lipid Research.

Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

R. McPherson, G. Fodor, J. Frohlich, 2006, The Canadian journal of cardiology.

Erythrocyte abnormalities in a hypoalphalipoproteinemia syndrome resembling fish eye disease

L. Wadsworth, J. Frohlich, D. Godin, 1988, European journal of haematology.

Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease.

M. Hayden, J. Collins, S. Rabkin, 2014, JIMD reports.

Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.

M. Hayden, A. Brooks-Wilson, J. Kastelein, 2000, The Journal of clinical investigation.

Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.

R. Hegele, D. Fitchett, G. Mancini, 2011, The Canadian journal of cardiology.

Homozygous Tangier disease and cardiovascular disease.

R. Lees, E. Schaefer, E. Janus, 1994, Atherosclerosis.

Dietary sitostanol reduces plaque formation but not lecithin cholesterol acyl transferase activity in rabbits.

J. Frohlich, P. J. Jones, F. Ntanios, 1998, Atherosclerosis.

Effective exercise modality to reduce insulin resistance in women with type 2 diabetes.

H. Tildesley, A. Ignaszewski, J. Frohlich, 2003, Diabetes care.

Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations.

C. Scudamore, J. Frohlich, M. Moghadasian, 2002, Archives of neurology.

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.

J. Crouse, M. Mercuri, J. Frohlich, 1999, The American journal of cardiology.

Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule

J. Frohlich, Sammy Y. Chan, M. Jawi, 2020, Journal of lipids.

The Role of Risk Factors in the Development of Atherosclerosis

S. Lear, J. Frohlich, M. Dobiášová, 2001, Critical reviews in clinical laboratory sciences.

Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

J. Frohlich, J. Genest, J. G. Fodor, 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population.

M. Hayden, J. Frohlich, S. Pimstone, 2001, Atherosclerosis.

The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.

G. Assmann, J. Kastelein, J. Frohlich, 1997, Journal of lipid research.

The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease.

A. Ignaszewski, M. Schulzer, G. Mancini, 2003, Journal of the American College of Cardiology.

Old and new risk factors for atherosclerosis and development of treatment recommendations

S. Lear, J. Frohlich, 2002, Clinical and experimental pharmacology & physiology.

"Tall oil"-derived phytosterols reduce atherosclerosis in ApoE-deficient mice.

B. McManus, J. Frohlich, M. Moghadasian, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography.

J. Frohlich, M. Dobiášová, 2003, Clinical chemistry.

Glomerular disease in hypercholesterolemic guinea pigs: a pathogenetic study.

J. Frohlich, A. Magil, T. Al-Shebeb, 1988, Kidney international.

Running title : Goal-inhibiting statin intolerance

R. Hegele, D. Fitchett, G. Mancini, 2016 .

Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E‐related disorders in humans

Mehrdad Nadji, B. McManus, C. Scudamore, 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Role of plant sterols in cholesterol lowering.

E. Trautwein, J. Frohlich, P. Dutta, 2004 .

Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects.

A. Lichtenstein, E. Schaefer, M. Jauhiainen, 2002, Journal of lipid research.

Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism.

A. Lichtenstein, E. Schaefer, M. Jauhiainen, 2001, Journal of lipid research.

Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses: Comparison with spousal pairs without personal and family history of atherosclerosis

J. Frohlich, K. Rašlová, B. Smolková, 2000 .

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects.

J. Frohlich, P. J. Jones, F. Ntanios, 1999, Metabolism: clinical and experimental.

Lipid transfer proteins, hypertriglyceridemia, and reduced high-density lipoprotein cholesterol.

J. Frohlich, D. Sparks, P. Pritchard, 1991, American heart journal.

Statin-Associated Muscle Adverse Events: Update for clinicians.

A. Ignaszewski, J. Frohlich, M. Al-Mohaissen, 2016, Sultan Qaboos University medical journal.

Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment.

J. Frohlich, H. Vaverkova, D. Novotný, 2005, Clinical biochemistry.

Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?

J. Frohlich, A. Sniderman, Saman Miremadi, 2002, Clinical chemistry.

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

B. G. Brown, A. Chait, J. Frohlich, 2004, The American journal of cardiology.

Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography.

John S. Hill, J. Frohlich, C. Heslop, 2010, Journal of the American College of Cardiology.

Exercise in a Healthy Heart Program: A Cohort Study

J. Frohlich, A. Al-Sarraf, K. Grierson, 2013, Clinical Medicine Insights. Cardiology.

Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality.

N. Anthonisen, J. Connett, D. Sin, 2011, European heart journal.

Pharmacology of drugs used to treat smoking cessation and obesity

G. Bondy, J. Frohlich, K. Johns, 2008 .

The Extensive Lifestyle Management Intervention (ELMI) following cardiac rehabilitation trial.

J. Spinelli, W. Linden, A. Ignaszewski, 2003, European heart journal.

A randomized controlled trial of an extensive lifestyle management intervention (ELMI) following cardiac rehabilitation: study design and baseline data

J. Spinelli, W. Linden, A. Ignaszewski, 2002, Current controlled trials in cardiovascular medicine.

Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.

Lawrence A Leiter, P. Jones, J. Frohlich, 2011, JAMA.

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1.

J. Frohlich, L. Brunham, Xuan Li, 2017, Journal of clinical lipidology.

Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization.

J. Frohlich, J. Genest, J. Davignon, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Cardiovascular risk and atherosclerosis prevention.

J. Frohlich, Ahmad Al-Sarraf, 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

Subclinical atherosclerosis in subjects with family history of premature coronary artery disease.

S. Lear, J. Frohlich, G. Mancini, 2008, American heart journal.

Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B.

J. Frohlich, G. Cheung, Y. Siow, 2001, Kidney international.

Paediatric type III dyslipidaemia: a case of vanishing hyperlipidaemia

J. Frohlich, Ahmad Al-Sarraf, G. Sarwal, 2012, BMJ Case Reports.

Homocyst(e)ine and Coronary Artery Disease: Clinical Evidence and Genetic and Metabolic Background

B. McManus, J. Frohlich, M. Moghadasian, 1997 .

Lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes.

J. Frohlich, R. Mcleod, Jiři Frohlich, 1986, Advances in experimental medicine and biology.

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

R. McPherson, G. Fodor, J. Frohlich, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Dramatic lowering of very high Lp(a) in response to niacin.

S. Rabkin, J. Frohlich, R. Saeedi, 2014, Journal of clinical lipidology.

Predictors of Metabolic Syndrome in Participants of a Cardiac Rehabilitation Program

A. Ignaszewski, S. Lear, J. Frohlich, 2012, ISRN cardiology.

Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome

B. G. Brown, A. Chait, L. Fisher, 2002 .

Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.

J. Kastelein, M. Mercuri, J. Kastelein, 2000, The American journal of cardiology.

Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography

J. Frohlich, M. Dobiášová, M. Cheung, 2011, Journal of Lipid Research.

The relationship between waist circumference and metabolic risk factors: cohorts of European and Chinese descent.

S. Lear, C. Birmingham, J. Frohlich, 2002, Metabolism: clinical and experimental.

Differential effects of simvastatin and atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐I are consistent across hypercholesterolemic patient subgroups

M. Mercuri, J. Frohlich, R. Scott, 2003, Clinical cardiology.

Dietary sitostanol and campestanol: Accumulation in the blood of humans with sitosterolemia and xanthomatosis and in rat tissues

D. S. Lin, J. Frohlich, A. Pappu, 2005, Lipids.

The effect of a dietary portfolio compared to a DASH-type diet on blood pressure.

Lawrence A Leiter, J. Frohlich, R. D. de Souza, 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Low prevalence of type 2 diabetes mellitus among patients with high levels of high-density lipoprotein cholesterol.

J. Frohlich, K. Humphries, M. Vrablik, 2013, Journal of clinical lipidology.

Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study

Q. Young, J. Frohlich, Quincy-Robyn Young, 2013, BMC Public Health.

A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy.

E. Schaefer, J. Frohlich, B. Asztalos, 2014, Journal of clinical lipidology.

Lipoprotein (a), an independent cardiovascular risk marker

J. Frohlich, R. Saeedi, 2016, Clinical Diabetes and Endocrinology.

Interaction of high density lipoprotein with adipocytes in a new patient with Tangier disease.

M. Hayden, R. McLeod, P. Julien, 1987, Clinical and investigative medicine. Medecine clinique et experimentale.

Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis.

J. Frohlich, D. Karásek, M. Halenka, 2009, Clinical biochemistry.

Niacin: from mechanisms of action to therapeutic uses.

J. Frohlich, M. Al-Mohaissen, S. Pun, 2010, Mini reviews in medicinal chemistry.

Dietary supplementation with fish gelatine modifies nutrient intake and leads to sex-dependent responses in TAG and C-reactive protein levels of insulin-resistant subjects

S. Weisnagel, A. Marette, J. Marois, 2012, Journal of nutritional science.

Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort

K. Walley, J. Frohlich, Keith R Walley, 2006, Canadian Medical Association Journal.

The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial.

J. Spinelli, W. Linden, A. Ignaszewski, 2006, American heart journal.

Statin resistant dyslipidemia in a patient treated with amiodarone

J. Frohlich, Min Li, Ahmad Al-Sarraf, 2011, BMJ Case Reports.

Abstract PR-04: Blood lipid and lipoprotein levels and the risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition

T. Pischon, M. Jenab, J. Frohlich, 2010 .

Reaching target lipid levels in patients at high risk of cardiovascular event: the experience of a Canadian tertiary care lipid clinic.

J. Frohlich, Daniel T. Holmes, F. Málek, 2007, Central European journal of public health.

Positive association of adiponectin with soluble thrombomodulin, von Willebrand factor and soluble VCAM-1 in dyslipidemic subjects.

J. Frohlich, D. Karásek, M. Halenka, 2013, Clinical biochemistry.

Carotid ultrasound, coronary calcium, and dyslipidemia patterns in the MESA (Multi-Ethnic Study of Atherosclerosis) cohort.

G. Mancini, J. Frohlich, 2010, Journal of the American College of Cardiology.

Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor.

J. Frohlich, M. Francis, Jiri J. Frohlich, 2001, Atherosclerosis.

Lipids and cardiovascular diseases.

J. Frohlich, A. Sniderman, 1999, The Canadian journal of cardiology.

Laboratory standardization of a large international clinical trial: the DAIS experience. DAIS Project Group. Diabetes Atherosclerosis Intervention Study.

J. Sundvall, C. Ehnholm, J. Frohlich, 2000, Clinical biochemistry.

Dyslipidaemia and coagulation defects of insulin resistance.

J. Frohlich, G. Steiner, G. Steiner, 2000, International journal of clinical practice. Supplement.

Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease

J. Frohlich, A. Mattman, Min Li, 2012, BMJ Case Reports.

Familial defective apolipoprotein B-100 in hypercholesterolemic Chinese Canadians: identification of a unique haplotype of the apolipoprotein B-100 allele.

M. Hayden, J. Frohlich, S. Pimstone, 1997, Atherosclerosis.

Atherogenic lipoprotein profile in families with and without history of early myocardial infarction.

J. Frohlich, K. Rašlová, M. Dobiášová, 2001, Physiological research.

Fish odour syndrome

J. Frohlich, G. Sinclair, Min Li, 2011, Canadian Medical Association Journal.

Coronary artery calcium findings in asymptomatic subjects with family history of premature coronary artery disease

B. Forster, G. Mancini, J. Frohlich, 2012, BMC Cardiovascular Disorders.

Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study

G. Mancini, A. Ignaszewski, J. Frohlich, 2008, BMC clinical pharmacology.

The Canadian lipid guidelines are difficult to model quantitatively.

J. Frohlich, Daniel T. Holmes, 2008, The Canadian journal of cardiology.

Positive association of adiponectin with soluble vascular cell adhesion molecule sVCAM-1 levels in patients with vascular disease or dyslipidemia.

J. Frohlich, D. Karásek, M. Halenka, 2008, Atherosclerosis.

Lack of benefit in treating high homocysteine levels with vitamins

A. Ignaszewski, J. Frohlich, D. Rippel, 2007 .

Coronary atherosclerosis in anorexia nervosa.

S. Lear, J. Frohlich, G. Mancini, 2003, The International journal of eating disorders.

A Rare Disease With Diverse Manifestations

C. Scudamore, J. Frohlich, M. Moghadasian, 2016 .

Follow-up of type III hyperlipoproteinaemia in a child

J. Frohlich, M. Fung, R. Bebb, 2001, The Lancet.

Assessment of atherogenic profile of plasma using estimation of cholesterol esterification rate in apolipoprotein B depleted plasma (FERHDL) and Logarithmically transformed ratio of triglyceride/HDL-cholesterol

J. Frohlich, M. Dobiášová, 1999 .

Original research article - Special issue: Cardiovascular Prevention Use of ezetimibe results in more patients reaching lipid targets without side effects

J. Frohlich, Daniel T. Holmes, B. Forer, 2014 .